Stay updated with breaking news from அலெக்ஸ் வேன் ரீஸ். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Press release content from Business Wire. The AP news staff was not involved in its creation. IVERIC bio, Inc. Announces Pricing of $100 Million Public Offering of Common Stock July 13, 2021 GMT NEW YORK (BUSINESS WIRE) Jul 12, 2021 IVERIC bio, Inc. (Nasdaq: ISEE) (the “Company”), today announced the pricing of an underwritten public offering of 11,650,000 shares of its common stock at a price to the public of $8.60 per share, less underwriting discounts and commissions. In addition, in connection with the offering, the Company has granted the underwriters an option for a period of 30 days to purchase up to an additional 1,747,500 shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares are being offered by the Company. ....
Message : Required fields BOSTON, May 07, 2021 (GLOBE NEWSWIRE) Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today presented preclinical data suggesting the utility of its lead clinical development candidate, INZ-701, as a potential treatment for ABCC6 Deficiency. The data, presented at the virtual European Calcified Tissue Society Annual Congress (ECTS, May 6-8), are the first to show that an enzyme replacement therapy (ERT) increased plasma pyrophosphate (PPi) levels and reduced calcification in an animal model of ABCC6 Deficiency. ABCC6 Deficiency is a rare, inherited disorder that can present as generalized arterial calcification of infancy (GACI) type 2 in infants and as pseudoxanthoma elasticum (PXE) in children and adults. This is one of several disorders with significant decrease in plasma PPi levels, a potent regulator of mineralization. In patients ....
Inozyme Pharma to Present Burden of Illness Data at the 2021 ACMG Annual Clinical Genetics Meeting BOSTON, April 08, 2021 (GLOBE NEWSWIRE) Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of abnormal mineralization, today announced that data from the burden of illness in infantile onset ABCC6 and ENPP1 deficiency study will be presented at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting taking place April 13-16, 2021. The following poster presentation will be available during the ACMG Annual Clinical Genetics Meeting beginning on Wednesday, April 14, 2021, at 7:00 a.m. ET: ....
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Inozyme Pharma Expands its Scientific Advisory Board Inozyme Pharma Inc.April 1, 2021 GMT BOSTON, April 01, 2021 (GLOBE NEWSWIRE) Inozyme Pharma, Inc., a rare disease biopharmaceutical company developing novel therapeutics for the treatment of disorders of abnormal mineralization, announced today changes to its scientific advisory board (SAB), including the addition of three leading key opinion leaders with specific expertise in the company’s lead indications: W Charles O’Neill IV, M.D., Director of the Ultrasonography Program in the Renal Division at Emory University School of Medicine ....
The Balancing Act® on Lifetime to Feature ENPP1 Deficiency Educational Episode to Highlight Symptoms of ENPP1 Deficiency and the Importance of Early Diagnosis BOSTON, March 11, 2021 (GLOBE NEWSWIRE) Inozyme Pharma, Inc., a rare disease biopharmaceutical company developing novel therapeutics for the treatment of disorders of abnormal mineralization, announced today that ENPP1 deficiency will be featured on The Balancing Act ® as part of the show’s recurring “Behind the Mystery of Rare and Genetic Diseases” series to raise awareness for this rare, debilitating, and life-threatening mineralization disease for which there are currently no approved treatment options. The episode will feature Janine Hicks, a patient living with ENPP1 deficiency; her parents, Donna and Peter Hicks; and Professor Zulf Mughal, a treating physician and researcher and Consultant in Pediatric Bone Disorders, Royal Manchester Children’s Hospital, Manchester University NHS Foundatio ....